Mysterious cells that secrete hormones in the large intestine play a key role in regulating body weight through their relationship with intestinal bacteria, a study led by UT Southwestern Medical Center researchers suggests. Their findings, published in Nature Metabolism, could lead to new treatments for obesity and extreme weight loss.
The study reported in the journal Nature provides a mechanistic explanation for the “obesity paradox” — that obesity can contribute to cancer progression but also improve response to immunotherapy.
Researchers at the Icahn School of Medicine at Mount Sinai have been awarded a $21 million grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH), to further advance understanding of an aging-related hormone known as follicle-stimulating hormone (FSH), including its potential role in obesity, osteoporosis, and Alzheimer’s disease.
The issue discusses population trends in obesity, the role of food insecurity and food-related behavior in obesity, how obesity affects predisposition to diseases and response to therapies, treatment and management options including exercise prescriptions, and the importance of a multidisciplinary approach in obesity management.
A team of Ochsner Health cardiologists recently published an article in the Journal of the American Medical Association (JAMA) Cardiology comparing two treatment strategies for patients with atrial fibrillation and obesity.
The summer holiday break is often considered a time of fun and relaxation for school children, but hand in hand with a respite from routine comes an increase in sedentary behaviour and screen time, and in turn, poorer health and academic outcomes.
Studies from multiple UChicago experts show that while GLP-1RA drugs are extremely effective for weight loss and Type 2 diabetes treatment, there's no one-size-fits-all solution and physicians and patients have to consider issues like cost and side effects.
The type of weight loss surgery women undergo before becoming pregnant may affect how much weight their children gain in the first three years of life, suggests a study being presented Monday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
A new study by researchers at the Case Western Reserve University School of Medicine reveals that the popular diabetes and weight-loss drugs Wegovy and Ozempic are linked to reduced incidence and recurrence of alcohol abuse or dependence.
GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
High insulin levels contribute to worse outcomes for Black women compared to white women who have an aggressive form of breast cancer called triple-negative breast cancer, according to a study presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Almost one out of five breast cancer survivors may experience weight gain of more than 10%, suggests a study presented Monday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. A number of factors are associated with excessive weight gain, the researchers found.
A new study led by researchers at the American Cancer Society (ACS) shows that older adult cancer survivors with excess body weight at the time of their first cancer diagnosis are at higher risk of developing a second cancer, especially an obesity-related cancer like breast or colorectal cancer.
A new, large study led by researchers at the American Cancer Society (ACS) shows adults sticking to an exercise program of 15 or more metabolic equivalent hours (MET) of physical activity per week (300 or more minutes of moderate activity or 150 or more minutes of vigorous activity) decreased their risk for cancer, including obesity-related cancers, compared with no intervention.
People under age 50 have a greater risk for heart attack or stroke if they’ve lived with obesity for 10 years, according to industry-sponsored research being presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Medications for type 2 diabetes and obesity known as GLP-1 receptor agonists may lower the risk of acute pancreatitis recurrence in people with obesity and those with type 2 diabetes, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Having medical conditions linked to obesity does not impact the total weight loss achieved with the anti-obesity medication tirzepatide, according to an industry-supported study being presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Showing results
1–1 of 1
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
